Image
Image_1_Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.pdf
| العنوان: | Image_1_Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram.pdf |
|---|---|
| المؤلفون: | Agnese Losurdo, Angelo Dipasquale, Laura Giordano, Pasquale Persico, Elena Lorenzi, Antonio Di Muzio, Chiara Barigazzi, James Korolewicz, Aman Mehan, Oreoluwa Mohammed, Benhard Scheiner, David J. Pinato, Armando Santoro, Matteo Simonelli |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, immunotherapy, early-phases clinical trials, prognostic scores, next-generations immunotherapies, immune-related adverse events |
| الوصف: | Introduction Identifying which patient may benefit from immunotherapeutic early-phase clinical trials is an unmet need in drug development. Among several proposed prognostic scores, none has been validated in patients receiving immunomodulating agents (IMAs)-based combinations. Patients and methods We retrospectively collected data of 208 patients enrolled in early-phase clinical trials investigating IMAs at our Institution, correlating clinical and blood-based variables with overall survival (OS). A retrospective cohort of 50 patients treated with IMAs at Imperial College (Hammersmith Hospital, London, UK) was used for validation. Results A total of 173 subjects were selected for analyses. Most frequent cancers included non-small cell lung cancer (26%), hepatocellular carcinoma (21.5%) and glioblastoma (13%). Multivariate analysis (MVA) revealed 3 factors to be independently associated with OS: line of treatment (second and third vs subsequent, HR 0.61, 95% CI 0.40-0.93, p 0.02), serum albumin as continuous variable (HR 0.57, 95% CI 0.36–0.91, p 0.02) and number of metastatic sites (<3 vs ≥3, HR 0.68, 95% CI 0.48-0.98, p 0.04). After splitting albumin value at the median (3.84 g/dL), a score system was capable of stratifying patients in 3 groups with significantly different OS (p<0.0001). Relationship with OS reproduced in the external cohort (p=0.008). Then, from these factors we built a nomogram. Conclusions Prior treatment, serum albumin and number of metastatic sites are readily available prognostic traits in patients with advanced malignancies participating into immunotherapy early-phase trials. Combination of these factors can optimize patient selection at study enrollment, maximizing therapeutic intent. |
| نوع الوثيقة: | still image |
| اللغة: | unknown |
| Relation: | https://figshare.com/articles/figure/Image_1_Refining_patient_selection_for_next-generation_immunotherapeutic_early-phase_clinical_trials_with_a_novel_and_externally_validated_prognostic_nomogram_pdf/25011653 |
| DOI: | 10.3389/fimmu.2024.1323151.s001 |
| الاتاحة: | https://doi.org/10.3389/fimmu.2024.1323151.s001 https://figshare.com/articles/figure/Image_1_Refining_patient_selection_for_next-generation_immunotherapeutic_early-phase_clinical_trials_with_a_novel_and_externally_validated_prognostic_nomogram_pdf/25011653 |
| Rights: | CC BY 4.0 |
| رقم الانضمام: | edsbas.BFD219D8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fimmu.2024.1323151.s001 |
|---|